[New drugs for indications currently treated by off-label drugs: intravitreal dexamethasone and ranibizumab].
A
A
Monzón Moreno
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000191:economics / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000191:economics / Q000627:therapeutic use; D003907:Dexamethasone / Q000008:administration & dosage / Q000627:therapeutic use*; D016527:Drug Costs; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000188:drug therapy*; D056687:Off-Label Use / Q000331:legislation & jurisprudence; D017239:Paclitaxel / Q000191:economics / Q000627:therapeutic use; D000069579:Ranibizumab; D013030:Spain; D014747:Vinblastine / Q000031:analogs & derivatives / Q000191:economics / Q000627:therapeutic use; D014822:Vitreous Body
D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D000972:Antineoplastic Agents, Phytogenic; C111217:vinflunine; D014747:Vinblastine; D003907:Dexamethasone; D017239:Paclitaxel; D000069579:Ranibizumab